745 ISSN 1750-743X Immunotherapy (2010) 2(6), 745–748 10.2217/IMT.10.66 © 2010 Future Medicine Ltd “Although it would be naive to conclude that biomarker programs are cheap and straightforward, it is likely to be a price worth paying in order to maximize the chance of success in the tortuous process of cancer drug development, and, ultimately, to provide better value for both patients and healthcare providers.”